Active Filter(s):
Details:
MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.
Lead Product(s): Live Attenuated Mycobacterium Tuberculosis Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: MTBVAC
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: IAVI
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 14, 2021